Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This entry refers to the collection of messenger RNAs (mRNAs) that are unintentionally targeted by a small interfering RNA (siRNA) designed to silence the Peroxisome proliferator-activated receptor gamma (PPARγ) gene. In the process of RNA interference, the guide strand of the siRNA can bind to transcripts other than the intended target if there is sufficient sequence complementarity, particularly within the 'seed region' (nucleotides 2-8) (Jackson et al., 2003). This phenomenon, known as off-target effects, can lead to the degradation or translational inhibition of numerous unintended genes, potentially causing cellular toxicity or confounding the interpretation of experimental data (Birmingham et al., 2006). While PPARγ itself is a key regulator of adipogenesis and glucose metabolism, the silencing of these 'other mRNAs' represents a significant hurdle in the development of specific RNAi-based therapeutics and research tools. Strategies to mitigate these effects include chemical modifications of the siRNA, such as 2'-O-methyl substitutions, and the use of sophisticated bioinformatic algorithms to minimize sequence overlap with the transcriptome (Fedorov et al., 2006).
The siRNA guide strand is loaded into the RNA-induced silencing complex (RISC), where it binds to mRNAs with partial complementarity, particularly in the 3' untranslated region (UTR), leading to translational repression or mRNA degradation (Jackson et al., 2003; Birmingham et al., 2006).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Off-target messenger RNAs of PPARγ small interfering RNA (PPARγ siRNA off-targets).